- Trials with a EudraCT protocol (242)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
242 result(s) found for: Chronic respiratory failure.
Displaying page 9 of 13.
EudraCT Number: 2014-004133-16 | Sponsor Protocol Number: IH141 | Start Date*: 2015-02-19 |
Sponsor Name:Hull and east Yorkshire Hospitals Trust | ||
Full Title: Exploratory multicentre prospective double blinded randomised controlled pilot study of the effect of intravenous iron supplementation(Monofer)in iron deficient but not anaemic patients with Chroni... | ||
Medical condition: Chronic Kidney Disease stages 3b to 5 with iron deficiency | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001629-28 | Sponsor Protocol Number: EYP001-201 | Start Date*: 2019-11-06 | |||||||||||
Sponsor Name:ENYO Pharma SA | |||||||||||||
Full Title: A Phase 2a, randomized, double-blind, placebo-controlled study of oral FXR modulator EYP001a combined with nucleos(t)ide analogues (NA) in virologically suppressed chronic hepatitis B patients to i... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000130-11 | Sponsor Protocol Number: EryDexFCTx1.0 | Start Date*: 2011-07-25 | ||||||||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | ||||||||||||||||||
Full Title: Clinical trials in rare diseases: therapeutic alternative to the use of oral corticosteroids in patients with cystic fibrosis underwent double lung transplantation. | ||||||||||||||||||
Medical condition: Double lung transplantation in patients with Cystic Fibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000919-22 | Sponsor Protocol Number: OMB114578 | Start Date*: 2011-09-14 | |||||||||||
Sponsor Name:University of Liverpool [...] | |||||||||||||
Full Title: RIAltO: A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL | |||||||||||||
Medical condition: Chronic Lymphocytic Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023777-19 | Sponsor Protocol Number: SToP-BPD | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Academic Medical Center | |||||||||||||
Full Title: Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants: the SToP-BPD study | |||||||||||||
Medical condition: bronchopulmonary dysplasia | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001540-56 | Sponsor Protocol Number: 208657 | Start Date*: 2019-08-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and cha... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) HU (Completed) ES (Ongoing) NL (Completed) DK (Completed) BE (Completed) DE (Completed) SE (Completed) IE (Completed) IT (Completed) GR (Completed) AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000827-13 | Sponsor Protocol Number: A5951001 | Start Date*: 2007-11-26 | |||||||||||
Sponsor Name:Pfizer Pharmaceutical Group | |||||||||||||
Full Title: LINEZOLID IN THE TREATMENT OF SUBJECTS WITH NOSOCOMIAL PNEUMONIA PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | |||||||||||||
Medical condition: MRSA Infection - Nosocomical Pneumenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002416-27 | Sponsor Protocol Number: INFECIR2 | Start Date*: 2013-10-23 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Fundacio Clinic per a la recerca biomedica | ||||||||||||||||||||||||||||||||||||||
Full Title: Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mo... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with advanced cirrhosis (serum creatinine > 1.2 mg/dl, serum sodium < 130 mEq/l and/or serum bilirubin > 4 mg/dl), signs of systemic inflammation and urinary infection, pneumonia, skin/sof... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: NO (Completed) ES (Ongoing) IT (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) NL (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000905-29 | Sponsor Protocol Number: RENOIR | Start Date*: 2022-04-12 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies | |||||||||||||
Medical condition: Covid-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002369-32 | Sponsor Protocol Number: 100-303 | Start Date*: 2020-07-31 | |||||||||||
Sponsor Name:Diffusion Pharmaceuticals Inc. | |||||||||||||
Full Title: Open-label, pharmacokinetic, pharmacodynamic, ascending dose safety lead-in followed by a single-center, placebo-controlled, double-blind, adaptive, safety and efficacy, pilot study of Trans Sodium... | |||||||||||||
Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001400-29 | Sponsor Protocol Number: P150302J | Start Date*: 2018-03-16 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Treatment of severe refractory systemic lupus erythematosus by injection of allogeneic mesenchymal stem cells derived from the umbilical cord - MSC SLE | |||||||||||||
Medical condition: Treatment of Systemic Lupus Erythematosus refractory to standard treatments. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004755-17 | Sponsor Protocol Number: MYST-FACT | Start Date*: 2024-10-01 | |||||||||||
Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO | |||||||||||||
Full Title: PHASE I/II CLINICAL TRIAL OF ALLOGENEIC BONE MARROW DERIVED MESENCHYMAL STROMAL CELL THERAPY FOR THE PREVENTION AND TREATMENT OF PULMONARY FIBROSIS SECONDARY TO POST-INFECTIVE ARDS OR ALLOIMMUNE RE... | |||||||||||||
Medical condition: PULMONARY FIBROSIS SECONDARY TO ARDS OR ALLOIMMUNE REACTION AFTER TRANSPLANTATION | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002904-13 | Sponsor Protocol Number: 0019 | Start Date*: 2006-11-01 | |||||||||||
Sponsor Name:Theravance, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infec... | |||||||||||||
Medical condition: Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) ES (Completed) SI (Completed) SK (Completed) LT (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002823-41 | Sponsor Protocol Number: AC-065B302 | Start Date*: 2019-06-03 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipa... | |||||||||||||
Medical condition: Chronic Thromboembolic Pulmonary Hypertension, inoperable or persistent/recurrent | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) BE (Completed) NL (Completed) HU (Completed) AT (Completed) BG (Completed) DK (Prematurely Ended) PT (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005651-21 | Sponsor Protocol Number: ONC001-CL-001 | Start Date*: 2021-05-26 | ||||||||||||||||
Sponsor Name:Oncorena AB | ||||||||||||||||||
Full Title: A phase I/II, open label, single arm study on safety, tolerability and anti -tumour efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma | ||||||||||||||||||
Medical condition: Metastatic Clear Cell Renal Cell Carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC) and with End-Stage Renal Disease (ESRD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002390-25 | Sponsor Protocol Number: E21-04 | Start Date*: 2022-01-20 | |||||||||||
Sponsor Name:Fab'entech | |||||||||||||
Full Title: A two-stage randomized, placebo-controlled, double-blind, phase 2a study to characterize the safety and pharmacokinetics of FBR-002 in patients hospitalized with COVID-19 need of supplemental oxyge... | |||||||||||||
Medical condition: COVID-19 in hospitalized patients in need of supplemental oxygen and at risk of severe outcome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001689-12 | Sponsor Protocol Number: MHIPS-2020-001 | Start Date*: 2020-04-11 |
Sponsor Name:MONTREAL HEART INSTITUTE | ||
Full Title: COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19) | ||
Medical condition: Men and women over 40 years of age, with a diagnosis of COVID-19 infection and at least one high risk criterion. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) FR (Prematurely Ended) GR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001411-25 | Sponsor Protocol Number: XPORT-COV-1001 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||
Full Title: A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection | |||||||||||||
Medical condition: Severe COVID-19 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012367-34 | Sponsor Protocol Number: BCX1812-301 | Start Date*: 2009-11-27 | |||||||||||
Sponsor Name:BioCryst Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard o... | |||||||||||||
Medical condition: Influenza | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) NL (Ongoing) LV (Prematurely Ended) CZ (Completed) DE (Prematurely Ended) HU (Completed) GB (Prematurely Ended) SK (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003187-37 | Sponsor Protocol Number: MK-5172-083 | Start Date*: 2016-01-25 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) with and without Ribavirin (RBV)... | |||||||||||||
Medical condition: Hepatitis C infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
